NCT03983031View on ClinicalTrials.gov

Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Obsessive-Compulsive DisorderTreatment Resistant Disorders
Interventions
DRUG

Rituximab

Infusion

Trial Locations (2)

70116

Region Örebro län, Örebro

70356

Region Örebro Län, Örebro

All Listed Sponsors
collaborator

Örebro University, Sweden

OTHER

lead

Region Örebro County

OTHER

NCT03983031 - Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019) | Biotech Hunter | Biotech Hunter